<Suppliers Price>

Peptide YY Fragment 3-36 human

Names

[ CAS No. ]:
126339-09-1

[ Name ]:
Peptide YY Fragment 3-36 human

[Synonym ]:
MFCD00165623

Biological Activity

[Description]:

Peptide YY (PYY) (3-36), human is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.

[Related Catalog]:

Signaling Pathways >> Others >> Others
Research Areas >> Metabolic Disease
Peptides

[Target]

Y2 receptor[1]


[In Vitro]

Peptide YY (PYY) (3-36), human is a Y2 receptor agonist, generated via cleaving the first two amino acids at the N terminus of PYY1-36 by enzyme dipeptidyl peptidase-IV (DPP-IV), and can reduces food intake[1].

[In Vivo]

In mice, actinonin significantly prolongs the anorectic effect of PYY3-36 (50 nmol/kg) and maintains higher PYY3-36 plasma levels than treatment with PYY3-36 alone[1].

[Animal admin]

Mice[1] Mice are divided into four treatment groups and administered an injection (maximum volume, 100 μL, sc) of either: 1) saline (n = 10), 2) phosphoramidon (10 mg/kg) (n = 10), 3) PYY3-36 (50 nmol/kg) (n = 10), or 4) PYY3-36 (50 nmol/kg) and phosphoramidon (10 mg/kg) (n = 10). This dose of phosphoramidon inhibits NEP activity for 4 h. Body weight is measured at 0 and 24 h after injection. Food intake is measured at 1, 2, 3, 4, 8, and 24 h after injection[1].

[References]

[1]. Addison ML, et al. A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36. Endocrinology. 2011 Dec;152(12):4630-40.


[Related Small Molecules]

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline

Chemical & Physical Properties

[ Molecular Formula ]:
C176H272N52O54

[ Molecular Weight ]:
3980.42

[ Appearance of Characters ]:
lyophilized powder

[ Storage condition ]:
−20°C

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

Articles

Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.

Br. J. Pharmacol. 116 , 2245-2250, (1995)

1. We have characterized pharmacologically the receptor subtype(s) responsible for the neuropeptide Y (NPY)-induced vasoconstriction in human cerebral arteries. NPY, PYY and several of their derivativ...

Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis.

Trends Pharmacol. Sci. 17 , 436-438, (1996)

Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.

Br. J. Pharmacol. 118 , 237-242, (1996)

1. The Y receptor subtype involved in the antagonism by neuropeptide Y (NPY) of intracisternal corticotropin-releasing factor (CRF)-induced inhibition of gastric acid secretion was studied in urethane...


More Articles


Related Compounds